Fig. 2From: Biweekly oxaliplatin plus S1 for Chinese elderly patients with advanced gastric or gastroesophageal junction cancer as the first-line therapy: a single-arm, phase 2 studyKaplan–Meier estimates of OS of advanced G/GEJ cancer patients treated with biweekly SOX. OS, overall survival; G/GEJ, gastric or gastroesophageal junctionBack to article page